This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site



Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Example content

Adverse event reporting can be found at the bottom of the page



Our BrandsOur Brands Ngenla® (somatrogon)Genotropin® (somatropin)Somavert® (pegvisomant)BeneFIX® (nonacog alfa)ReFacto AF® (moroctocog alfa)ATGAM® (horse anti-human T-lymphocyte immunoglobulin)Oxbryta® (voxelotor)VYNDAQEL® (tafamidis)Therapy areaTherapy areaAcromegalyGrowth DisordersHaemophiliaTransthyretin Amyloid Cardio-myopathy (ATTR-CM)Support and ResourcesSupport and ResourcesContact us Meet the Team Endocrine editionMeet the Team Sickle cell editionMeet the Team Transthyretin Amyloid Cardiomyopathy edition

Prescribing information can be found within the Our BRANDS section.

Welcome to Rare Diseases

There are over 7,000 rare diseases in the world today and counting.1 While these diseases may be individually rare they are collectively common, affecting approximately 3.5 million people in the UK alone.1 So if you don’t already know someone affected directly, you probably don’t need to speak to too many people before you will.

Select a therapy area below to find out more  Acromegaly

Definition of acromegaly, typical characteristics and diagnosis of this chronic disease

Explore Acromegaly 
Growth Disorders

Understand more about these rare disorders and the support available

Explore Growth Disorders 

Learn more about this rare, lifelong condition requiring constant and careful management

Explore Haemophilia Loading
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Understand the causes of the disease plus current and emerging treatment strategies

Explore            ATTR-CM Loading
About Rare DiseasesOver the past decade scientific advances have increased our understanding of rare diseases and their underlying causes, enabling the development of treatment options. But today, only around 5% of rare diseases have a licensed treatment, this gap in care has spurred a sense of urgency within Pfizer Rare Disease - to find new, potentially life-changing approaches. 2

We're focused on the following areas; Haematology, Neurology, Amyloidosis, Pulmonology, Endocrinology and Nephrology. A key focus is advancing our gene therapy capabilities. We believe gene therapy has the potential to provide meaningful improvements in the lives of millions of people living with rare diseases, and we pride ourselves on being a leader in this space. 

With rare diseases, patients are the true experts and we listen to, learn from, and work in close collaboration with patients at every stage - from R&D to treatment delivery. Every strategy, every decision is made with the patient in mind. 
The Rare Disease FrameworkThe Rare Disease Framework is a policy document, published in 2021, by the UK Government and delivery partners across the healthcare industry with aims to ensure improvements are continually being made to the treatment, diagnosis and lives of people living with a rare disease in the UK. Defined as a condition which affects less than 1 in 2000 people3, rare diseases are estimated to impact over 5% of the UK population (approx. 3.5 million people)1.

The framework is being developed in two phases, the first of which sets out four key priorities identified to relieve the challenges faced by the rare disease community. These include:

Priority 1: Helping patients get a final diagnosis faster
Priority 2: Increasing awareness of rare diseases among healthcare professionals
Priority 3: Better coordination of care
Priority 4: Improving access to treatment and specialist care

The second phase of the framework is ensuring each of the UK nations develop an action plan containing steps to meet the requirements of the framework with their own arrangements, best tailored to benefit their own populations. The wider rare disease community will also support action plans and will be under review every 1 – 2 years.1

To achieve the outcomes for both phases, 5 ‘underpinning themes’ have been recognised to support the priorities of the framework and will act as key enablers to facilitate and maintain the framework objectives.

These priorities and underpinning themes have been identified and refined with the help of the National Conversation on Rare Diseases Survey seeking the views of patients, families, clinicians, researchers, and patient organisations in a programme of engagement to understand the challenges faced by those living and working with rare diseases.

The objectives placed in the Rare Disease Framework provide an opportunity to provide meaningful change for the rare disease community. By using the framework as a foundation for change, the quality of patients’ lives can continue to improve.

Please click on the link to view the full rare diseases framework policy document - The UK Rare Diseases Framework 
2023 England Rare Diseases Action Plan Published

On 28th February 2023, the Department of Health and Social Care (DHSC) published its second Rare Diseases Action Plan for England to coincide with Rare Diseases Day. The Action Plan is divided into two sections (1. Progress from 2022 and 2. Priorities for 2023) and structured around the four priorities of the UK Rare Diseases Framework, and notes that progress on the ATMP strategic approach is ongoing. The DHSC will continue to monitor progress on actions and will work with the wider system, including industry, to develop metrics and methodology to measure the improvement of the lives of people living with Rare Diseases in the UK across the 4 priority areas.

The full Action Plan can be found here

Progress from 2022 – key highlights: 4

  • During 2022, NHSE developed a map of programmes that promote access to drugs and are actively using a ‘preparedness template’ with industry to develop a shared understanding of the service implications for new drugs, approved by NICE, so patients benefit as early as possible 
  • On the ATMP strategic approach, the progress report notes that this is ongoing. NHSE remains actively involved with ATMP Engage, the patient collaboration co-chaired by Genetic Alliance UK and the Cell and Gene Therapy Catapult. It says in establishing a structured approach to ATMP commissioning, NHSE has engaged with a range of stakeholders across industry, as well as individual patient groups and providers. Using horizon scanning, NHSE has also instigated structured proactive engagement with individual ATMP manufacturers 12 to 24 months prior to marketing authorisation. NHSE has said as this activity continues to iterate over time, there is no planned strategic publication that will accompany this work 
  • An analytical approach has been developed to measure both the overall and geographical uptake of drugs for patients with rare diseases. This combines data from several sources, such as Blueteq and locally held NHSE systems 

Priorities for 2023 – key highlights: 4

  • The DHSC will commission policy research through an NIHR open call to develop an effective method for measuring the time to diagnosis for both genetic and non-genetic rare conditions with input from the rare diseases community
  • To provide continued assurance of the high-quality of services for patients with rare diseases, NHSE will establish a Highly Specialised Services Programme Board (HSSPB), which will meet quarterly 
  • NHSE, MHRA and NICE will review the impact of the Early Access to Medicines Scheme (EAMS), the Innovative Licensing and Access Pathway (ILAP) and the Innovative Medicines Fund (IMF), including their effectiveness in improving access to treatments for people living with rare diseases

The DHSC have said that over the course of the year, they will monitor the progress of these actions closely with delivery partners. A third Action Plan will be published in 2024, which will again report on progress against the actions set out in this Plan, as well as proposing updated and new actions. 

Our BRANDS ​ Ngenla®▼ (somatrogon)

For UK Healthcare Professionals Only. Information on 
NGENLA (somatrogon).
Ngenla® (somatrogon) Prescribing information

Explore Ngenla 
Genotropin® (somatropin)

For UK Healthcare Professionals Only. Information on 
Genotropin (somatropin rbe)
Genotropin® (somatropin) Prescribing information

Learn about Genotropin Loading
Somavert® (pegvisomant)

For UK Healthcare Professionals Only. Information on 
Somavert (pegvisomant
Somavert® (pegvisomant) Prescribing information

Discover Somavert  Loading
BeneFIX® (nonacog alfa)

For UK Healthcare Professionals Only. Information on 
BeneFIX® (nonacog alfa).
BeneFIX® (nonacog alfa) Prescribing information

More on BenefixLoading
ReFacto AF® (moroctocog alfa)

For UK Healthcare Professionals Only. Information on 
ReFacto AF® (moroctocog alfa).
ReFacto AF® (moroctocog alfa)  Prescribing information

Get to know Refacto  Loading
ATGAM®▼ (horse anti-human T-lymphocyte immunoglobulin)

For UK Healthcare Professionals Only. Information on 
ATGAM®▼ (horse anti-human T-lymphocyte immunoglobulin)
ATGAM® (horse anti-human T-lymphocyte immunoglobulin)
Prescribing information

Get to know ATGAMLoading
Oxbryta®▼ (voxelotor)

For UK Healthcare Professionals Only. Information on 
Oxbryta®▼ (voxelotor)
Oxbryta® (voxelotor) Prescribing information

Get to know OxbrytaLoading
VYNDAQEL®▼ (tafamidis)

For UK Healthcare Professionals Only. Information on 
VYNDAQEL®▼ (tafamidis)
VYNDAQEL® (tafamidis) Prescribing information

Get to know VYNDAQELLoading
Contact us 

To find out more about supporting your patients. 

Contact us Loading
Stay up to date 


Receive the latest relevant healthcare, medical and promotional information about medicines promoted by Pfizer by email.

  • Promotional information and materials
  • Invitations to Pfizer organised meetings
  • Links to available online resources
Register Here Loading


  1. Department of Health and Social Care. The UK Rare Diseases Framework. January 2021 Accessed February 2024

  2. Clarke. S. Ellis. M. & Brownrigg, J.The impact of rarity in NICE’s health technology appraisals. Orphanet J Rare Dis 16, 218 (2021) 

  3. Genetic Alliance UK. What is a rare disease? Accessed February 2024

  4. Department of Health and Social Care. England Rare Diseases Action Plan 2023. February 2023 Accessed February 2024

PP-BEN-GBR-0648. February 2024.

Adverse events should be reported. Reporting forms and information can be found at or search 

for MHRA Yellow Card in Google Play or Apple App Store


Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ


Copyright © 2024 Pfizer Limited. All rights reserved.


VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
You are now leaving PfizerPro
​​​​​​​You are now leaving Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021